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Background: Mutations in the valosin-containing protein (VCP) gene were first found to cause inclusion- body
myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD). Mutations in the VCP gene were
later reported to occur in familial amyotrophic lateral sclerosis (ALS). But the role of VCP in the neurodegenerative
processes that occur in ALS remains unknown. The purpose of the present study was to elucidate the role of VCP
in the neurodegeneration seen in sporadic and VCP mutant ALS.
Results: Immunohistochemistry demonstrated that the frequency of distinct VCP-positive nuclei of spinal motor
neurons of patients with sporadic ALS (SALS) and the ALS with VCP novel mutation (ALS-VCP, M158V) was
increased, compared with that of the control cases. No VCP-positive inclusion bodies were observed in SALS
patients, a ALS-VCP patient or in control subjects. Neuropathologic examination of the ALS-VCP case showed loss of
motor neurons, the presence of Bunina bodies, and degeneration of the corticospinal tracts. Bunina bodies detected
in this case were confirmed to show immunohistochemical and ultrastructural features similar to those previously
described. Furthermore, neuronal intracytoplasmic inclusions immunopositive for TAR DNA-binding protein 43 kDa
(TDP-43), phosphorylated TDP-43, ubiquitin (Ub), p62, and optineurin were identified in the spinal and medullary
motoneurons, but not in the neocortex. Gene analysis of this ALS-VCP patient confirmed the de novo mutation of
M158V, which was not found in control cases; and bioinformatics using several in silico analyses showed possible
damage to the structure of VCP. Immunocytochemical study of cultured cells showed increased cytoplasmic
translocation of TDP-43 in cells transfected with several mutant VCP including our patient’s compared with
wild-type VCP.
Conclusion: These findings support the idea that VCP is associated with the pathomechanism of SALS and familial
ALS with a VCP mutation, presumably acting through a dominant-negative mechanism.
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Valosin-containing protein (VCP) is a ubiquitous member
of the AAA-ATPase supergene family. VCP is known to
play an important role in cellular activities including ubi-
quitin (Ub) -dependent protein degradation [1], chromatin-
associated protein degradation [2], messenger ribonucleic
acid (mRNA) metabolism [3], autophagy [4], anti-apoptotic
function [5], and post-mitotic Golgi apparatus reassembly
[6]. Mutations in the VCP gene were first found to cause
inclusion-body myopathy with early-onset Paget disease
and frontotemporal dementia (IBMPFD) [7,8]. IBMPFD is
an autosomal dominantly inherited disorder with variable
penetrance of 3 predominant phenotypic features, i.e., my-
opathy, Paget disease of bone, and frontotemporal demen-
tia (FTD) [9]. The penetrance of the gene is 82% for
myopathy, 49% for Paget’s disease, and 30% for FTD [10].
IBMPFD patients with VCP mutations can develop disor-
ders in other organ systems including sphincters [11], car-
diac muscles [12], auditory system [13], and liver [14], as
well as in visuoconstructive ability [14]. Neurodegenerative
diseases associated with a VCP mutation encompass scapu-
loperoneal muscular dystrophy and dropped head syn-
drome [15], Parkinson’s disease [16-18], hereditary spastic
paraplegia [19], and cerebellar ataxia [20]. In addition to
mutations in VCP [7,8], mutations in Heterogeneous Nu-
clear Ribonucleoprotein A2B1 (HNRNPA2B1) and Heteroge-
neous Nuclear Ribonucleoprotein A1 (HNRNPA1) [21] have
been identified in families with IBMPFD. Given these ob-
servations, the name of multisystem proteinopathy (MSP)
has been proposed, using the nomenclature of MSP1 for
IBMPFD caused by a VCP mutation, MSP2 for IBMPFD
related to an HNRNPA2B1 mutation, MSP3 for IBMPFD
related to an HNRNPA1 mutation, and MSP4 for IBMPFD
due to some unidentified gene [22]. Clinically, 37.7% pa-
tients of IBMPFD with a VCP mutation (MSP1) develop
FTD [9]. FTD cases with a VCP mutation (MSP1) present
with TAR DNA-binding protein 43 kDa (TDP-43) and
ubiquitin-positive short dystrophic neurites and frequently
lentiform neuronal intranuclear inclusions in their neocor-
tex [23-25]. On the other hand, only rare VCP-positive
neuronal intranuclear inclusions are detected, and those
that are detected lack the characteristic lentiform morph-
ology [23]. This finding suggests that TDP-43 and ubiquitin
positive-inclusions do not contain VCP and supports the
idea that VCP gene mutations in IBMPFD produce a
dominant-negative loss of VCP function [23,25].
Mutations in the VCP gene were later reported to occur
in familial amyotrophic lateral sclerosis (ALS) [26]. A recent
study with a large data set of patients with VCP mutations
showed that 8.9% of these patients developed ALS [27].
Features of ALS with VCP mutations (ALS-VCP) are simi-
lar to those of sporadic ALS (SALS), including bulbar signs,
spasticity, hyperreflexia, fasciculations, and electrophysio-
logical evidence of lower motor neuron involvement suchas denervation and reinnervation [27]. The neuropathology
of ALS-VCP has been briefly described in 2 cases to date
[26,28]. Both reports described TDP-43-positive intracyto-
plasmic inclusions in the motor neurons. These facts sug-
gest that the neuropathologic features of ALS-VCP could
be similar to those of SALS and that SALS would share its
pathogenic role with ALS-VCP cases through dysfunction
of VCP. To confirm this hypothesis, it is of importance to
elucidate detailed pathological features of ALS-VCP and to
compare them with those of SALS. However, specific inclu-
sion pathology including their immunohistochemical prop-
erties and distributions, as well as detailed cytopathology of
motor and non-motor neurons and glial cells, remain to be
explored.
VCP immunoreactivity has been observed in Lewy bod-
ies in Parkinson’s disease and dementia with Lewy bodies,
in neuronal nuclear inclusions in polyglutamine diseases
and intranuclear inclusion body disease, in Marinesco
bodies [29], and in epidermal cells from patients with
SALS [30]. VCP-positive nuclei have also been reported in
neocortical neurons [31] and in muscle cells [20] from
IBMPFD cases with a VCP mutation (MSP1). However,
the distribution of VCP in ALS-VCP cases is unknown.
Moreover, it remains to be investigated whether a VCP
mutation leads to VCP-positive inclusions in the ALS
phenotype, and whether VCP-positive structures are
present in the motor neurons of SALS patients.
To elucidate the role of VCP in neurodegenerative
processes in ALS, in the present study we examined the
neuropathology of a patient with ALS and Paget disease
of bone with a novel VCP mutation, as well as the im-
munohistochemical localization of VCP in SALS cases
and in the ALS-VCP patient.
Materials and methods
VCP immunohistochemistry in ALS
We investigated specimens from lumbar spinal cord, hippo-
campus, and the motor cortex from 9 patients with patho-
logically confirmed SALS (age range, 54–82 years; mean,
63.2 years; 6 men and 3 women), 8 control subjects (age
range, 50–86 years; mean, 69.5 years; 6 men and 2 women),
and 1 patient with ALS associated with a novel VCP muta-
tion. The clinical profiles of all of these cases are summa-
rized in Table 1. Among SALS cases, there was no familial
case and no history of IBM, Paget disease or FTD.
For VCP immunohistochemistry, formalin-fixed, par-
affin-embedded 6-μm-thick sections were deparaffi-
nized and immunostained for VCP. We applied 2
distinct primary antibodies for VCP(mouse monoclonal
[Cat. No. ab11433], Abcam plc, Cambridge, UK; 1:500;
and rabbit polyclonal [Cat. No. AP6920b], Abgent, San
Diego, California, USA; 1:75). Bound antibodies were
detected with the appropriate VECTASTAIN Elite ABC
Kit (Vector Laboratories, Burlingame, California, USA).












1 75 M Chronic lymphocitic leukemia 2.5 NA 0
2 75 M Cerebral infarction 1 NA 0
3 86 M Cerebral infarction 5 NA 0
4 75 M Meningitis 3 NA 1.7
5 83 F Intracerebral hemorrhage 12 NA 4
6 52 M Cerebral infarction 12 NA 8.9
7 50 F Myotonic Dystrophy 10 NA 0
8 60 M Myasthenia Gravis 2.5 NA 0
ALS cases
9 54 F SALS 3.5 11 26.3
10 82 M SALS 1.5 14 0
11 62 M SALS 1.5 14 0
12 56 F SALS 22.5 20 0
13 65 M SALS 1.5 23 8.3
14 63 M SALS 1.5 23 15
15 64 M SALS 3 24 17.6
16 65 M SALS 16 24 94.1
17 58 F SALS 3.5 35 47.1
18 41 M VCP-ALS 2 48 7.7
M male, F female, VCP Valosin-Containing Protein, SALS sporadic amyotrophic lateral sclerosis, VCP-ALS ALS with M158V VCP mutation.
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antibodies with an appropriate amount of phosphate-
buffered saline solution containing 3% bovine serum albu-
min. No deposits of reaction products were seen in the
sections thus treated. Procedures involving the use of hu-
man material were performed in accordance with ethical
guidelines set by Kyoto University.
For quantitative study of VCP-positive nuclei of the
motor neurons, we obtained 3 distinct sections from each
case, taken at an interval of 30 μm, to avoid counting the
same nucleus twice. All observations were made by 2 ex-
aminers who had no information regarding the clinical his-
tory and condition of the individual providing the spinal
specimen. Only anterior horn cells (AHCs) with a distinct
nucleus and nucleolus were counted. The frequency of
VCP-positive motor neurons in the lumbar cord was com-
pared between control patients and SALS patients by the
nonparametric Mann–Whitney U test using Prism software
(GraphPad, La Jolla, USA).
Clinical features of the ALS patient with a VCP mutation
Our patient was a 41-year-old Japanese man without
any family history of ALS, IBM, Paget disease or FTD
(Figure 1a). He had developed right arm and leg weak-
ness at age 36. Based on the results of elevated alkaline
phosphatase up to 2,968 IU/l, bone radiographs, andelectromyography, he was diagnosed at age 37 as having
ALS and Paget disease of bone. He gradually developed
weakness of arms and legs, dysarthria, dysphagia, and re-
spiratory failure, which required percutaneous endoscopic
gastrostomy and noninvasive positive-pressure ventilation
at age 38. He was referred to our hospital at age 39. Exam-
inations disclosed weakness in all extremities, muscle at-
rophy in the distal arms, and fasciculation in the right leg.
Atrophy or fasciculation of the tongue was not evident.
Patellar tendon reflexes were brisk, but Achilles tendon
reflexes and those in the upper limbs were decreased. Nei-
ther pathologic reflexes nor clonus was observed in the
extremities. Neuropsychological tests showed no evidence
of FTD. A computed tomography (CT) scan showed sys-
temic osteolytic change, but no atrophy of the brain. Nee-
dle electromyography (EMG) showed active and chronic
denervation potential including spontaneous discharges
and late recruitment in the left arm and leg. A frozen
muscle specimen from the right quadriceps muscle at this
time showed neurogenic changes without evidence of
IBM. Base on the revised El Escorial criteria [32], the pa-
tient was diagnosed as clinically possible ALS.
His extremities gradually became weaker, resulting in a
bedridden condition. Shortly after he developed a fracture
of the right femoral bone, he died of respiratory failure at
the age of 41. Throughout the clinical course he did not
Figure 1 Genetic information. (a) The presented case had no family history of ALS, dementia, myopathy or Paget disease. Family members
with diagonal black lines had already died. The ages indicated are those at the time of the proband’s death. (b) The proband carried the
missense mutation of the VCP gene (c. 472A > G, p.M158V). Neither the father nor the mother carried the VCP mutation identified in the proband.
(c) Sequence alignment for amino acids revealed the mutation site to be conserved across different species. (d) Domain structure of VCP protein
and mutation site in this case and in reported mutations (Mutations with autopsy are shown in red type) associated with ALS and IBMPFD.
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sonism, spastic paraplegia, cerebellar ataxia or decubitus
ulcer. Also, the patient did not have any abnormalities in
cardiac, hepatic, visual, auditory, sensory or autonomic
systems. No frozen brain tissue was available.
Genetic analysis
Genetic analysis of VCP, Cu/Zn superoxide dismutase 1
(SOD1), TDP-43, fused in sarcoma (FUS), Charged mul-
tivesicular body protein 2b (CHMP2B), angiogenin,Sequestosome 1 (SQSTM1), and chromosome 9 open
reading frame 72 (C9ORF72) was approved by either the
Kyoto University Graduate School of Medicine Ethical
Committee or Hiroshima University Ethical Committee,
and written informed consent was obtained from the
above patient prior to his demise. DNA was extracted
from a blood sample; and by using previously reported
primers, we amplified the exons of each gene and se-
quenced them on anABI310 sequencer (Applied Biosys-
tem, Foster City, California, USA). To detect C9ORF72
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reaction, as reported previously [33]. As a result we identi-
fied a novel heterozygous M158V mutation in the VCP
gene (Figure 1b). This mutation was not present in the
1000 Genomes project (http://www.1000genomes.org/),
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) or in the Hu-
man Genetic Variation Browser (includes genetic variations
determined by exome sequencing of 1,208 Japanese individ-
uals and genotyping data of common variations obtained
from a cohort of 3,248 individuals [http://www.genome.
med.kyoto-u.ac.jp/SnpDB/]). The other genes were normal.
Conservation analysis of the mutated amino acid by using
National Center for Biotechnology (NCBI) HomoloGene
demonstrated conservation among species at the mutation
site (Figure 1c). The mutation site in this case (amino acid
158 in VCP) was located near the reported mutation sites
(amino acids 155 [26] and 159 [28] in VCP) within the
same domain (Figure 1d). In Figure 1d, mutation sites in
VCP gene associated with ALS and IBMPFD are also listed
from the literature [8,9,13-15,26,28,31,34-39].
His parents were still alive and not affected with ALS
or any other neurodegenerative diseases. His father was
73 years of age and had been diagnosed with prostate
cancer, whereas his mother was 71 years old and healthy.
Neither parent carried the VCP mutation identified in
the proband. Haplotype analysis using 15 short tandem
repeat markers supported their genetic kinship, confirm-
ing that the mutation occurred de novo in the present
case. No sample from the patient’s brother was available.
Neuropathologic examinations
For neuropathologic examinations, formalin-fixed, paraffin-
embedded 6-μm-thick sections were deparaffinized and
stained with hematoxylin and eosin (H&E) or used for Klü-
ver-Barrera (KB) staining. For immunohistochemistry, after
antigen retrieval by heat/autoclaving (10 min at 121°C in
10 mM anhydrous citric acid buffer, pH 6.0), the sections
were immunostained as described above.
The antigens recognized by the primary antibodies used
in this study were the following: TDP-43(rabbit polyclonal
[Cat No. 10782-2-AP], ProteinTec Group Inc., Chicago,
Illinois, USA; 1:200), phosphorylated TDP-43 (mouse
monoclonal [Cat No. TIP-PDT-M01], Cosmo Bio Co.,
Ltd., Tokyo, Japan; 1:2000), trans-Golgi-network (sheep
polyclonal [Cat No. 610832], Novus Biologicals, Inc,
Littleton, Colorado, USA; 1:250), VCP(mouse monoclonal
[Cat No. ab11433], Abcam plc, Cambridge, UK; 1:500;
rabbit polyclonal [Cat No. AP6920b], Abgent, San Diego,
California, USA; 1:75), FUS(rabbit polyclonal [Cat No.
HPA008784], Sigma-Aldrich Inc., St. Louis, Missouri,
USA; 1:100), CD68 (mouse monoclonal [Cat No. M0814],
DAKO, Glostrup, Denmark; 1:100), p62(mouse monoclo-
nal [Cat No. 610832], Becton Dickinson and Company,
Franklin Lakes, New Jersey, USA; 1:700), ubiquitin(rabbitpolyclonal [Cat No. U5379], Sigma-Aldrich Inc., St. Louis,
Missouri, USA; 1:100), and optineurin (rabbit polyclonal
[Cat No. 100000], Cayman Chemical Company, Ann
Arbor, Michigan, USA; 1:200).
Electron microscopy
In the case with the VCP mutation, the sample from
formalin-fixed medulla was fixed in 2% glutaraldehyde
with phosphate buffer (pH 7.4). After fixation, sections
were cut into pieces about 1 mm thick, postfixed with
1% osmium tetroxide for 2 h, dehydrated, and embedded
in epoxy resin. Each block was then cut into semithin
sections about 1 μm in thickness and stained with tolui-
dine blue. Appropriate regions were subsequently cut
into ultrathin sections and stained with uranyl acetate
and lead citrate for electron microscopy.
Proteomics analysis
The effect of the newly detected missense mutation
(M158V) and previously reported mutations of 2 autopsied
ALS-VCP cases (R155H and R159H) was analyzed with
Mutation Taster (http://www.mutationtaster.org), Sorting
Intolerant From Tolerant (SIFT, http://sift.bii.a-star.edu.sg/),
and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/).
Vectors for in vitro analysis
To assess the functional importance of the novel mutation
identified in this study, we created vectors (pcDNA3) ex-
pressing wild-type (WT) VCP and mutant VCPs (R155H,
M158V, R159H and A232E) tagged with FLAG at their N-
terminus.
Cultured cells
SH-SY5Y and human embryonic kidney 293 T (HEK293T)
cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum, 1%
non-essential amino acids, and 1% penicillin-streptomycin-
L glutamine sodium.
Plasmids
To generate FLAG-tagged VCP, we obtained WT VCP
complementary deoxyribonucleic acid (cDNA) from a
cDNA library and generated sequence variants, including
R155H (464G >A), M158V (472A >G), R159H (476 G >
A) and A232E (695C > A). WT and mutant VCPs were
generated by PCR with primer pairs used to change the
nucleotides and then inserted into the Not I/BamH I clon-
ing site of the pcDNA3 vector. All constructs were verified
by using the 3130xl Genetic Analyzer (Life Technologies,
Carlsbad, California, USA. Cultured cells were transfected
with the vector by using a FuGene HD transfection kit
(Roche, Basel, Switzerland) according to the manufac-
turer’s protocol.
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Cells were lysed in lysis buffer containing 10 mM Tris–HCl
(pH 7.6), 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate (Na-DOC), 0.1% sodium dodecyl sulfate
(SDS), and a protease inhibitor cocktail (Complete EDTA-
free protease inhibitor; Nacalai Tesque). Nuclei and mem-
brane fractions were removed by centrifugation. Lysates
were separated by SDS-poly-acrylamide gel electrophoresis
(SDS-PAGE), and proteins were then transferred to a poly-
vinylidene difluoride (PVDF) membrane. The membrane
was incubated with the appropriate primary antibody,
followed by incubation with horseradish peroxidase (HRP)-
conjugated anti-rabbit or anti-mouse IgG (Santa Cruz Bio-
technology Inc, Dallas, Texas, USA) secondary antibody.
Immunoreactive proteins were visualized by using the
Pierce ECL Western Blotting Substrate (Thermo Scientific
Pierce, Kanagawa, Japan) and an LAS3000 scanning system
(Fuji Film, Tokyo, Japan). The following primary antibodies
were used in the immunoblot analysis: anti-VCP (rabbit
polyclonal [Cat No. AP6920b], Abgent, San Diego,
California, USA; 1:200) and anti-β-actin (mouse mono-
clonal [Cat No. A5441], Sigma-Aldrich Inc., St. Louis,
Missouri, USA; 1:2,000).
Immunocytochemistry
SH-SY5Y and HEK293T cells transfected with FLAG-
conjugated WT or mutant VCP were fixed and immuno-
stained with anti-TDP-43 or anti-FLAG, and stained with
DAPI, at 48 h post-transfection. For immunofluorescence
analysis of cell cultures, cultured cells were fixed with 4%
PFA for 20 min, washed 3 times with PBS (2 min each),
and then rendered permeable and blocked with 0.2%
Triton X-100/5% goat serum in PBS for 15 min. The
transfected cells were incubated with primary antibodies
(anti-TDP-43 antibody, rabbit polyclonal, ProteinTech,
1:1000 and anti-FLAG M2, mouse monoclonal, Sigma-
Aldrich Inc., St. Louis, Missouri, USA; 1:500, diluted in
PBS containing 0.2% Triton X-100/5% goat serum) over-
night and washed 3 times with PBS (5 min each). After
the final wash, the cells were incubated with secondary
antibodies (Alexa Fluor 488 donkey anti-rabbit IgG (H +
L) or Alexa Fluor 546 donkey anti-mouse IgG (H + L), di-
luted in PBS containing 0.2% Triton X-100/5% goat
serum) for 1 h, washed 3 times with PBS (5 min each),
and mounted with Vectashield plus DAPI (Vector Labora-
tories, Burlingame, California, USA). Digital imaging was
performed with an OLYMPUS FV-100 IX microscope
(Olympus, Tokyo, Japan) using FV-10-ASW 3.1 software
(Olympus). A blinded examiner counted more than 100
FLAG-tagged VCP-expressing cells from separate cultures
for the presence of cytoplasmic TDP-43-positive cells. Re-
sults were analyzed by One-way ANOVA of Bonferroni’s
multiple-comparison test using Prism software (Graph-
Pad, La Jolla, USA).Results
Immunohistochemistry for VCP in control subjects, SALS
patients, and the VCP mutant case
Two distinct anti-VCP antibodies applied in the present
study gave the same results.
In the 8 controls, VCP-positive nuclei or cytoplasm
was rarely observed in the AHCs investigated (Figure 2a);
only a few nuclei of AHCs showed faint immunoreactiv-
ity against VCP (Figure 2a inset). Glial nuclei were virtu-
ally not stained in these subjects (Figure 2b). In contrast,
AHCs from 9 SALS cases frequently showed positive
VCP immunoreactivity in the cytoplasm and in the nu-
cleus (Figure 2c). The staining intensity of neuronal nu-
clei of the SALS cases was much greater than that in the
control subjects. Within the cytoplasm, the deposits of
immunoreaction product were diffusely distributed, but
this antibody recognized no intranuclear inclusion,
skein-like inclusion, round hyaline inclusion or Bunina
body. Moreover, the glial nuclei were also stained in the
cases with SALS (Figure 2d). However, VCP-positive glial
cytoplasmic inclusions (GCIs) were not observed.
We also identified some neuronal (Figure 2e) and glial
(Figure 2f ) nuclei that were immunoreactive for VCP in
the ALS case with the heterozygous M158V VCP muta-
tion (case 18 in the Table). In the ALS-VCP case, VCP
immunoreactivity in the AHCs was less robust than that
in the SALS cases. No VCP-positive inclusions were de-
tected in any of the cases investigated.
In the motor cortex and hippocampus, there was no
significant immunoreactivity for VCP except for faint
immunoreactivity of glial nuclei.
The frequency of VCP-positive nuclei in the lumbar
cord of patients with SALS (mean ± standard deviation,
26.1 ± 31.5) was significantly higher (p < 0.05, Mann–
Whitney U test) than that for the control subjects (1.8 ±
3.2%; Figure 2g). In the ALS-VCP case 7.7% of the AHC
nuclei were VCP positive. On serial section analysis,
there was no apparent relationship between VCP immu-
noreactivity and intracytoplasmic TDP-43 accumulation.
Neuropathologic examinations of the patient with M158V
ALS-VCP
Frozen muscle specimens from the right quadriceps
muscle at age 39 showed neurogenic changes without evi-
dence of IBM (Figure 3a). In the immunohistochemical in-
vestigation, TDP-43 was normally detected in the muscle
nuclei, which showed no abnormal inclusions (Figure 3b).
Immunostaining for neither VCP nor OPTN revealed any
abnormal inclusions.
At autopsy of the M158V ALS-VCP patient, pneumo-
nia, fatty liver, and atheromatous plaques of the aorta
were recognized. Microscopic examination of the verte-
bra revealed mixed osteoclastic-osteoblastic activity and
a chaotic picture of trabecular bone (“mosaic” pattern)
Figure 2 Immunohistochemistry of VCP in the spinal cords. (a,b)
In the control case, neuronal (a, arrows) and glial (b, arrows) nuclei are
devoid of immunoreactivity. The nucleus of this AHC (a, inset, arrow) in
the control case was stained faintly with the anti-VCP antibody. (c,d) In
the ALS cases the same antibody distinctly immunolabels nuclei of the
AHCs (c, arrows) and those of the glial cells (d, arrows). The cytoplasm of
the indicated AHC (c, arrowhead) is also stained diffusely. (e,f) In the
ALS-VCP patient a nucleus of an AHC (e, arrow) and glial nuclei (f, arrows)
give positive staining with the anti-VCP antibody. (g) The frequency of
VCP-positive neuronal nuclei in the lumbar cord of the patients with
SALS (mean ± standard deviation, 26.1 ± 31.5%) was significantly higher
than that of the controls (1.8 ± 3.2%). Values are the means of the
percentage of VCP-positive neuronal nuclei in each case; and error
bars represent the standard deviation (*p < 0.05, Mann–Whitney
U test). Immunohistochemistry was performed with the rabbit
polyclonal antibody against VCP. Scale bars = 25 μm.
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(Figure 3c).
Neuropathologically, the formalin-fixed brain weighed
1,435 g. Macroscopic examination showed no evidence of
cerebral atrophy (Figure 3d, e). In H&E- and KB-stained
sections, the spinal anterior horns and the corticospinal
tracts showed evidence of degeneration, especially in the
lumbar cord (Figure 3f). Cervical and lumbar cord showed
cell loss with gliosis in the anterior horns (Figure 3g).
Onuf ’s nucleus and Clarke’s column were preserved. H&E-
stained sections revealed the presence of Bunina bodies
(Figure 3h) and spheroids in the anterior horns of the cer-
vical and lumbar cords.
Immunohistochemical investigation demonstrated TDP-
43-positive intracytoplasmic inclusions in the AHCs
(Figure 4a). GCIs positive for TDP-43 were sparsely scat-
tered in the spinal cord (Figure 4b). The TDP-43-positive
intracytoplasmic inclusions were also reactive with the anti-
ubiquitin antibody (Figure 4c,d). The nucleus of these
inclusion-bearing neurons was invariably immunonegative
for TDP-43 (Figure 4c). Analysis of consecutive sections re-
vealed that these TDP-43-positive inclusions were also react-
ive with anti-p62 antibody (Figure 4e,f) and anti-OPTN
antibody (Figure 4g,h). However, TDP-43-positive inclusions
(Figure 4i) were indiscernible on the VCP-immunostained
sections (Figure 4j). Careful examination of 164 AHCs in 8
VCP-stained sections from the cervical, thoracic, and lum-
bar spinal cords revealed no immunopositive inclusions with
any of the VCP antibodies. Analysis of serial sections dis-
closed no apparent correlation between the presence of
TDP-43-positive inclusions and nuclear and cytoplasmic
distribution of VCP immunoreactivity in AHCs. In the su-
perior frontal cortex, temporal cortex, motor cortex, and
hippocampus, there was no significant immunoreactivity
withVCP antibody.
Immunohistochemical investigation of the Golgi appar-
atus revealed characteristic fragmentation of it in the
AHCs (Figure 4k), whereas non-motor neurons in the
posterior horn had preserved Golgi apparatuses (Figure 4l).
Using the same method reported previously [39], we
found that in our case 61.5% (16/26) of the AHCs from 3
distinct spinal cord segments had a fragmented Golgi ap-
paratus. In the corticospinal tracts, immunostaining for
CD68 showed infiltration of CD68-positive microglia.
In the hypoglossal nuclei, the motoneurons were depleted
in number. Within the cytoplasm of the residual neurons
Bunina bodies and TDP-43- and p62-positive inclusions
were identified. The Bunina bodies were immunopositive
for cystatin C (Figure 4m). Electron microscopy demon-
strated Bunina bodies consisting of irregularly shaped
electron-dense material containing vesicles (Figure 5a-c).
Betz cells were not apparently depleted. Hippocampal
sclerosis was not found. In the primary motor, superior
frontal, and temporal cortices, putamen, thalamus,
Figure 3 Photographs and photomicrographs of general pathology and neuropathology of the ALS patient with the VCP mutation. (a,b)
In this muscle specimen from the right quadriceps muscle, large-group atrophy indicating neurogenic changes is demonstrated, whereas no evidence
of IBM is observed (a). The muscle nuclei are normally immunopositive with the anti-TDP-43 antibody (b, arrows), but abnormal inclusions are not
detected. (c) H&E staining of a vertebra demonstrates irregular broad trabeculae with disorganized cement lines appearing in a mosaic pattern. (d,e)
Macroscopically, the brain shows no apparent atrophy. (f) A KB-stained lumbar spinal cord reveals degeneration of the corticospinal tract (f, arrow). (g)
A section of cervical cord stained by H&E shows neuronal loss with gliosis in the anterior horn. (h) Typical Bunina bodies (arrow) are evident in the
cytoplasm of this cervical AHC. Scale bars= 250 μm (a), 200 μm (b), 50 μm (c), 1 mm (f), 100 μm (g), and 12.5 μm (h).
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nuclear or intracytoplasmic inclusions or GCIs found
by any of the staining procedures, including p62
immunohistochemistry.
By amyloid β and AT8-immunohistochemistry, this
case showed no senile plaque, but only a few isolated
neurofibrillary tangles in the hippocampus and amygdala
(CERAD 0, Braak-Braak stage II). Immunostaining for
α-synuclein and FUS revealed no pathologies.
Bioinformatics and in vitro studies
The effect of the newly detected missense mutation on
VCP protein structure was analyzed by in silico analysis
using different software. In Mutation Taster (http://
www.mutationtaster.org), M158V was estimated to be
disease causing (probability > 0.9999), and no Single Nu-
cleotide Polymorphism (SNP) was found in the site of
mutation. The known disease-causing VCP mutations
R155H and R159H were also diagnosed as disease caus-
ing (probability > 0.9999) in Mutation Taster.
In SIFT (http://sift.bii.a-star.edu.sg/) the M158V muta-
tion, as well as the known mutation R155H, was nottolerated (p = 0.00), meaning that the mutation is deleteri-
ous. On the other hand, the known mutation R159H
[28,34,38] was tolerated (p = 0.07, in tolerant threshold
<0.05), although the p-value was near the threshold.
Polyphen-2 (http://genetics.bwh.harvard.edu/pph/) analysis
showed possible damage to the structure by M158V, as in-
dicated by a Position-Specific Independent Counts (PSIC)
value of 0.896 (sensitivity: 0.82; specificity: 0.94), R155H
was analyzed to be possibly damaging with a score with
PSIC value 0.849 (sensitivity: 0.83; specificity: 0.93); al-
though R159H ,which is indeed a disease-causing mutation,
was predicted to be benign with a score of PSIC value 0.1
(sensitivity: 0.93; specificity: 0.85). Taken together, in silico
analysis strongly suggested that out novel mutation M158V
is pathogenic.
To assess the functional importance of the novel muta-
tion identified in our patient, we created mammalian ex-
pressing vectors for WT VCP and mutant VCPs (R155H,
M158V, R159H, and A232E) tagged with FLAG at their
N-terminus. Immunoblotting detected overexpression of
WT and mutant VCP in the transfected SH-SY5Y cells
(Figure 6a) and HEK293T (Additional file 1: Figure S1a),
Figure 4 Representative photomicrographs of the lumbar anterior horn (a-l) and the hypoglossal nucleus (m). Intracytoplasmic inclusion
bodies immunoreactive for TDP-43 are identifiable in the lumbar AHCs (a, arrows). A glial cytoplasmic inclusion (GCI) is evident with the anti-TDP-43
antibody (b, arrow). Analyses of consecutive sections indicated that TDP-43-positive inclusions in the AHCs (c, e, g, i, arrows) are also positive for
ubiquitin (Ub; d, arrow), for p62 (f, arrow), and for OPTN (h, arrow), but devoid of immunoreactivity for VCP (j, arrow). The nucleus of the inclusion-
bearing neuron lacks immunolabeling for TDP-43 (c, e arrowhead). Fragmentation of the Golgi apparatus is apparent in the AHCs immunostained with
TGN-46, a marker protein of the Golgi, in comparison with the preserved Golgi apparatus in the non-motor neuron of the posterior horn (l, arrow). A
Bunina body in the hypoglossal nucleus is immunopositive for cystatin C (m). Scale bars = 25 μm (a, c-m), 12.5 μm (b).
Figure 5 Electron microscopy of Bunina bodies. Three instances of Bunina bodies with irregularly shaped, amorphous, electron-dense material
including vesicles and cisternae in the motor neurons of hypoglossal nuclei are depicted. Scale bars = 1 μm (a-c).
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Figure 6 In vitro studies (SH-SY5Y cells). Immunoblotting detects overexpression of wild-type (WT) and mutant VCPs in transfected SH-SY5Y
cells at 48 hours after transfection (a). Expression of any mutant VCP (R155H, M158V, R159H or A232E) is associated with significantly more
cytoplasmic TDP-43 (b, c). Values are the means from 5 trials; error bars represent standard deviation; *p < 0.05, One-way ANOVA of Bonferroni’s
multiple-comparison, compared with mock and WT. The arrows in “b” indicate cytoplasmic TDP-43-positive cells.
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cells, at 48 hours after transfection. TDP-43 is a predom-
inantly a nuclear protein, and translocation of it from the
nucleus to the cytoplasm and aggregation therein are fea-
tures of previously reported types of mutant VCP-related
ALS [26,28]. Mutations in VCP were also reported to
cause abnormal TDP-43 translocation in cultured cells in-
cluding SH-SY5Y [40] and HEK293T [41]. So we investi-
gated whether our novel mutation (M158V) caused the
translocation of TDP-43 from the nucleus to the cyto-
plasm. Immunocytochemistry showed TDP-43 to be lo-
cated in the nuclei of mock-transfected cells and in those
transfected with WT-VCP (Figure 6b). In the mutant
VCP-expressing cells, immunoreactivity of TDP-43 was
often observed in the cytoplasm by 48 hours after trans-
fection (Figure 6b). However, no evident aggregation of
TDP-43 or VCP was observed in the transfected cells.
Quantitative evaluation of cytoplasmic TDP-43-positive
cells demonstrated that the expression of mutant VCP
was significantly associated with the presence of cytoplas-
mic TDP-43 (Figure 6c). There was no statistical differ-
ence in the number of cells with cytoplasmic TDP-43
between the cultured cells transfected with different VCPmutations. In the study using HEK293T, an increase in
cytoplasmic TDP-43 translocation was also observed in
cells transfected with mutant VCP (Additional file 1:
Figure S1b, c).
Discussion
In the present study, we provided detailed neuropathology
of an ALS case with the novel M158V VCP mutation, fo-
cusing on the similarity and difference to sporadic ALS. In
addition, for the first time we demonstrated that the fre-
quency of AHCs with VCP-immunoreactive cytoplasm
and nucleus was increased in SALS patients as well as in
this mutant case as compared with that in the controls.
Besides concomitant Paget disease of bone, the neuro-
logical manifestations and neuropathologic findings of our
novel ALS-VCP patient were indistinguishable from those
of the SALS patients. To date, 2 autopsied ALS-VCP cases
with distinct mutations have been reported [26,28]. Clinic-
ally, both cases were diagnosed as ALS without symptoms
of FTD. The initial patient was associated with an R155H
VCP mutation. Because of the limitation of specimen
availability, neuropathologic examinations of this case
were confined to brainstem and spinal cord motor neurons,
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Bunina bodies and TDP-43-positive cytoplasmic inclusions
with concomitant loss of nuclear staining in the surviving
motor neurons [26]. The disease of the second autopsied
ALS-VCP patient was associated with an R159H VCP mu-
tation. Neuropathologic description of this case was also
limited, literally describing the presence of p62-, ubiquitin-,
and TDP-43-positive inclusions. Additionally, they indi-
cated a few p62- and ubiquitin-positive inclusions in the
neurons of the hippocampal granular layer and frontotem-
poral lobes [28]. Although neocortical inclusion pathology
was not apparent in our novel ALS-VCP case, the patient
exhibited otherwise similar neuropathologic findings as re-
ported in the previous 2 cases. Furthermore, we demon-
strated that in our mutant case TDP-43 was co-localized
with ubiquitin, p62, and optineurin, but not with VCP, in
the cytoplasmic inclusions in the AHCs. TDP-43-positive
GCIs were obviously present. The lack of VCP immunore-
activity in the TDP-43-positive inclusions may imply that
the M158V mutant VCP would have lost ability to associate
with aggregated TDP-43. In addition, we disclosed that the
Bunina bodies in our ALS-VCP patient showed immuno-
histochemical and ultrastructural properties indistinguish-
able from those observed in SALS patients. Furthermore,
we identified fragmented Golgi apparatuses in our mutant
case. This finding is noteworthy, because several reports
have described that the Golgi apparatus is frequently frag-
mented in the AHCs of patients with SALS [42-44]. It is
plausible that VCP dysfunction led to vulnerability of the
Golgi apparatus in the present case, because VCP plays an
important role in assembly of the Golgi apparatus mem-
brane [45]. Taken together, our observations on the neuro-
pathology of the present ALS-VCP case resembled
considerably those on that of SALS, supporting the idea
that VCP would underlie the pathomechanism of SALS.
Patients with FTD in IBMPFD associated with a VCP
mutation are known to show lentiform intranuclear inclu-
sions in the neurons of their neocortex [23-25]; however,
the present case showed no such inclusions there. One
possibility for this discrepancy would be the presence of
modifier genes. Kimonis et al. evaluated modifier genes in
a database of 231 members of 15 original families with
IBMPFD and suggested a potential link between the
APOE 4 genotype and FTD [10]. Alternatively, the muta-
tion site might influence the phenotype. Recently, a study
using a large data set of patients with VCP mutations sug-
gested that several mutations (R155C, A232E) are corre-
lated with a severe phenotype and reduced survival;
although the precise genotypic correlation with respect to
VCP mutation has not been elucidated yet, because some
groups of mutations were very small in number [27].
The mutation site of our case (M158V) was very close
to the reported sites of mutation leading to the ALS
phenotype (R155H [26] and R159H [28]). In protein featureanalysis with Mutation Taster, these mutations were shown
to be disease causing. (Although only the R159H mutation
was analyzed as moderately damaging in SIFT and
Polyphen-2, this mutation in ALS and IBMPFD was re-
ported to occur in various cases [28,34,38]) All 3 of these
sites are located within the N-terminal domain, which con-
tains ubiquitin and cofactor-binding domains (Figure 1d)
[12]. The accumulation of p62 and OPTN in our case sug-
gests that the autophagy system was defective in this ALS-
VCP patient, because VCP [46-48], p62 [49], and OPTN
[50] play important roles in the autophagy-dependent pro-
tein clearance system. Our results and previous reports
[40,41] revealed that cells transfected with mutant VCP
showed abnormal TDP-43 translocation. These results sup-
port the notion that neurodegeneration in VCP mutant
cases would be attributable to dysfunction of protein clear-
ance systems, including ubiquitin-dependent protein deg-
radation and autophagy.
We did not detect VCP-positive inclusion bodies in our
case with M158V ALS-VCP. The absence of VCP inclu-
sions in our patient is in consistent with previous findings
obtained from FTD patients with VCP mutations
[14,23,25]. The lack of VCP-positive inclusion bodies
makes a toxic gain-of-function mechanism implausible.
On the other hand, since normal VCP [1] and mutant
VCP [46] are reported to form heteromeric complexes, a
mutant VCP could conceivably impair the formation of
properly functioning hexamers, thus having a dominant-
negative effect [25].
Immunohistochemical investigations on the SALS cases
revealed, similar to those on the ALS-VCP patient, in-
creased frequencies of VCP-immunoreactive structures
such as neuronal cytoplasm, neuronal nuclei, and glial nu-
clei. These findings suggest that SALS could share its
pathomechanism with ALS-VCP through dysfunctional
VCP. The cytoplasm of AHCs in SALS was moderately
and diffusely immunoreactive for VCP. Endoplasmic
reticulum (ER) stress due to accumulation of misfolded
proteins [51,52] and activated autophagy [53] in the cyto-
plasm have been reported to occur in SALS cases. Consid-
ering that VCP governs protein degradation processes in
both ER-associated ubiquitin-dependent protein degrad-
ation and autophagy [1,4], the increase in cytoplasmic
VCP in SALS may reflect a process that modifies these
protein degradation systems. Neuronal and glial nuclei
were more frequently immunopositive for VCP in SALS
cases than in the controls. VCP-positive nuclei have also
been detected in the neocortical neurons [31] and muscle
cells [20] in IBMPFD cases with a VCP mutation (MSP1).
On the other hand, in our study the frequency of VCP-
positive neuronal nuclei in the ALS-VCP case was lower
than that of these nuclei in the SALS cases, presumably
because of the functional loss of the M158V mutant VCP
to recognize intranuclear ubiquitinated proteins. Recently,
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ome stability through the degradation of chromatin-
associated proteins [2]. VCP is recruited at nuclear sites of
damaged DNA and facilitates degradation of ubiquitinated
chromatin-associated proteins to regulate DNA repair and
transcription [54-56]. Notably, VCP regulates splicing pat-
tern [3] and chromatin-associated proteins including RNA
polymerase II subunit 1 (Rpb1) [56], which plays an im-
portant role in producing heterogeneous nuclear RNA
(hnRNA). It is noteworthy that the alternative splicing of
hnRNA is regulated by hnRNP A2/B1 and hnRNP A1
[57], which are the products of causative genes of MSP2
and MSP3 [21,22]. The dysfunction of these proteins, in-
cluding VCP, hnRNP A1, and hnRNP A2/B1, could play
an IBMPFD (MSP) pathogenic role through disruption of
RNA metabolism and transcription processes. The in-
crease in nuclear VCP in the ALS cases observed in the
present study could be associated with the process by
which VCP is recruited for intranuclear protein degrad-
ation to maintain the RNA metabolism and the transcrip-
tion process. Alternatively, increased intranuclear VCP
accumulation in ALS implicates loss-of-function mechan-
ism of VCP as a pathogenesis of this disorder. Yang H
et al. proposed that aggregtes of polyQ-expanded Atx3 se-
quester VCP into protein inclusions, and leads to neuro-
degeneration. It could be possible that VCP is entrapped
by other intranuclear protein aggregation [58].
Our neuropathological investigations support the idea
that VCP was associated with the pathomechanism of
SALS and FALS with a VCP mutation. For determin-
ation of the pathological importance of VCP in these
disorders, further studies with additional cases are
warranted.
Additional file
Additional file 1: Figure S1. In vitro studies (HEK 293 T cells).
Immunoblotting shows overexpression of wild-type (WT) and mutant
VCPs of transfected HEK 293 T cells at 48 hours after transfection (a).
Cells expressing any of the mutant VCPs show an increased number of
expressing cytoplasmic TDP-43 compared with the cells transfected with
mock or WT VCP by 48 hours after transfection (b, c). Values are the
means from 3 trials; error bars represent standard deviation; *p < 0.05,
One-way ANOVA of Bonferroni’s multiple-comparison, compared with
mock and WT. The arrows in “c” indicate cytoplasmic TDP-43-positive
cells.
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